New York Yankees Legend Lou Piniella Teams Up With Cytogen Corporation, American Cancer Society, National Prostate Cancer Coalition, and Prostate Cancer Foundation to Raise Awareness for Prostate Cancer

NASDAQ Market Open Ceremony to Launch Fourth Annual

`Screen, Stage and Support' Campaign



Free Prostate Cancer Screening Offered in Front of NASDAQ MarketSite



Sep 08, 2004, 01:00 ET from Cytogen Corporation

    PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Cytogen Corporation
 (Nasdaq:   CYTO) today announced that Lou Piniella, Tampa Bay Devil Rays'
 manager and former New York Yankee, along with advocates from three leading
 patient organizations, will help to launch the Company's fourth annual
 "Screen, Stage and Support" campaign to promote prostate cancer education and
 awareness.  The campaign will kick off during Prostate Cancer Awareness Month
 with a special event at the NASDAQ MarketSite at 4 Times Square in New York,
 NY, on Thursday, September 9, 2004, at 9:30 a.m.
     Following the event, Cytogen is sponsoring free prostate cancer screening
 exams that will be offered by the National Prostate Cancer Coalition (NPCC) in
 conjunction with the American Cancer Society (ACS) from 10 a.m. to 6 p.m., in
 a mobile screening unit outside the NASDAQ MarketSite on 43rd Street as part
 of the "Drive Against Prostate Cancer" campaign.
     "Prostate cancer has had a presence in both my personal and professional
 lives - members of my family have battled the disease, along with fellow
 baseball managers Joe Torre and Dusty Baker," said Lou Piniella.  "I am glad
 to help promote prostate cancer education and awareness through the 'Screen,
 Stage and Support' campaign.  It is important that men take an active role in
 their health by getting screened regularly - I get tested every year and urge
 all men to do the same.  On September 9, I will be the first man screened in
 front of the NASDAQ MarketSite."
     "We are pleased that Lou Piniella is joining us to help raise awareness
 for this devastating disease during Prostate Cancer Awareness Month," said
 Michael Becker, President and CEO of Cytogen Corporation.  "Early detection,
 accurate staging, and proper treatment and support are essential aspects of
 this disease, and with Lou's participation in addition to advocates from three
 leading patient organizations, we hope to reach many more men with this
 important message."
     Prostate cancer is the second leading cause of cancer-related death among
 men.  According to the ACS, in 2004 alone, 230,110 men are expected to be
 diagnosed with the cancer and approximately 29,900 will die from the disease.
 
     About "Screen, Stage and Support"
     "Screen, Stage and Support" was started in 2001 by Cytogen Corporation to
 help patients, families and caregivers recognize the important role that
 proper screening, diagnosis, treatment and support can have for anyone
 affected by prostate cancer.  The campaign is designed to focus on the three
 key aspects of prostate cancer detection and treatment: screen, stage and
 support.
     Screen: When prostate cancer is diagnosed early, before it has spread
 outside the prostate gland, the odds for five-year survival are nearly
 100 percent through localized treatments.  The ACS recommends that men 50 and
 older get screened annually through a prostate-specific antigen (PSA) blood
 test and digital rectal exam (DRE); men at higher risk, such as
 African-Americans and those with a family history of prostate cancer, should
 begin early detection screening at age 45.  Stage:  Once a diagnosis of
 prostate cancer has been confirmed with a biopsy, doctors typically identify
 the "grade" and "stage" of the disease.  The grade is an estimate of the
 tumor's aggressiveness.  The stage refers to the extent and location of the
 cancer and whether or not it has spread beyond the prostate gland.  The grade
 and stage are the keys to defining the course of treatment the doctor will
 recommend.  Support:  Prostate cancer patients also require support in coping
 with the physical and emotional aspects of the disease, including the pros and
 cons of different treatment and palliative options, which can be obtained
 through patient advocacy groups such as the ACS, NPCC, and Prostate Cancer
 Foundation.
     The "Screen, Stage and Support" program has gained significant momentum
 and recognition over the past four years and it has continued to grow,
 providing patient education in the form of video, print and live seminars.
 For a free copy of the "Screen, Stage and Support" brochure, call
 1-800-833-3533 or visit http://www.cytogen.com, which is not part of this
 press release.
     In addition to the Manhattan screening event in front of the NASDAQ
 MarketSite, this year's program offers two additional days of free prostate
 cancer screening in New York City.  On September 8, the NPCC's "Drive Against
 Prostate Cancer" mobile screening unit will be at the Harlem YMCA from 9 a.m.
 to 12 p.m. and 2 p.m. to 6 p.m.  Then on September 10, the unit will be at the
 Bedford-Stuyvesant Restoration Corporation in Brooklyn from 9 a.m. to 12 p.m.
 and 2 p.m. to 6 p.m.
 
     About Cytogen Corporation
     Founded in 1980, Cytogen Corporation of Princeton, NJ, is a product-
 driven, oncology-focused biopharmaceutical company that develops and
 commercializes a balanced portfolio of oncology products that address the
 unmet medical needs of patients and the physicians that serve them.  Cytogen
 directly markets QUADRAMET(TM) (samarium Sm-153 lexidronam injection),
 PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111
 capromab pendetide, and NMP22(R) BLADDERCHEK(R) (nuclear matrix protein-22) in
 the United States.  Cytogen has exclusive United States marketing rights to
 COMBIDEX(R) (ferumoxtran-10), an investigational molecular imaging agent
 consisting of iron oxide nanoparticles for use in conjunction with magnetic
 resonance imaging to aid in the differentiation of cancerous and non-cancerous
 lymph nodes, which is under review by the U.S. Food and Drug Administration.
 Cytogen is also developing therapeutics targeting prostate-specific membrane
 antigen (PSMA), a protein highly expressed on the surface of prostate cancer
 cells and the neovasculature of solid tumors.  Full prescribing information
 for the Company's products is available at http://www.cytogen.com or by
 calling 1-800-833-3533.  For more information, please visit the Company's
 website at http://www.cytogen.com, which is not part of this press release.
 
     About Market Open Web Cam
     The Market Open ceremony can be viewed online through the NASDAQ web cam
 at http://www.nasdaq.com/reference/marketsite_about.stm.  Windows Media Player
 is required for the web cam to load properly.  Viewers are advised to access
 the web cam at 9:15 a.m. to allow time for loading; at 9:20 a.m. the web cam's
 view will be switched from the MarketSite Tower to inside the NASDAQ studio.
 
     This press release contains certain "forward-looking" statements within
 the meaning of the Private Securities Litigation Reform Act of 1995 and
 Section 21E of the Securities Exchange Act of 1934, as amended.  All
 statements, other than statements of historical facts, included in this press
 release regarding our strategy, future operations, financial position, future
 revenues, projected costs, prospects, plans and objectives of management are
 forward-looking statements.  Such forward-looking statements involve a number
 of risks and uncertainties and investors are cautioned not to put any undue
 reliance on any forward-looking statement.  There are a number of important
 factors that could cause Cytogen's results to differ materially from those
 indicated by such forward-looking statements.  In particular, Cytogen's
 business is subject to a number of significant risks, which include, but are
 not limited to: the risk of obtaining the necessary regulatory approvals; the
 risk of whether products result from development activities; the risk of
 shifts in the regulatory environment affecting sales of Cytogen's products
 such as third-party payor reimbursement issues; the risk associated with
 Cytogen's dependence on its partners for development of certain projects, as
 well as other factors expressed from time to time in Cytogen's periodic
 filings with the Securities and Exchange Commission (the "SEC").  As a result,
 this press release should be read in conjunction with Cytogen's periodic
 filings with the SEC.  The forward-looking statements contained herein are
 made only as of the date of this press release, and Cytogen undertakes no
 obligation to publicly update such forward-looking statements to reflect
 subsequent events or circumstances.
 
 

SOURCE Cytogen Corporation
    PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Cytogen Corporation
 (Nasdaq:   CYTO) today announced that Lou Piniella, Tampa Bay Devil Rays'
 manager and former New York Yankee, along with advocates from three leading
 patient organizations, will help to launch the Company's fourth annual
 "Screen, Stage and Support" campaign to promote prostate cancer education and
 awareness.  The campaign will kick off during Prostate Cancer Awareness Month
 with a special event at the NASDAQ MarketSite at 4 Times Square in New York,
 NY, on Thursday, September 9, 2004, at 9:30 a.m.
     Following the event, Cytogen is sponsoring free prostate cancer screening
 exams that will be offered by the National Prostate Cancer Coalition (NPCC) in
 conjunction with the American Cancer Society (ACS) from 10 a.m. to 6 p.m., in
 a mobile screening unit outside the NASDAQ MarketSite on 43rd Street as part
 of the "Drive Against Prostate Cancer" campaign.
     "Prostate cancer has had a presence in both my personal and professional
 lives - members of my family have battled the disease, along with fellow
 baseball managers Joe Torre and Dusty Baker," said Lou Piniella.  "I am glad
 to help promote prostate cancer education and awareness through the 'Screen,
 Stage and Support' campaign.  It is important that men take an active role in
 their health by getting screened regularly - I get tested every year and urge
 all men to do the same.  On September 9, I will be the first man screened in
 front of the NASDAQ MarketSite."
     "We are pleased that Lou Piniella is joining us to help raise awareness
 for this devastating disease during Prostate Cancer Awareness Month," said
 Michael Becker, President and CEO of Cytogen Corporation.  "Early detection,
 accurate staging, and proper treatment and support are essential aspects of
 this disease, and with Lou's participation in addition to advocates from three
 leading patient organizations, we hope to reach many more men with this
 important message."
     Prostate cancer is the second leading cause of cancer-related death among
 men.  According to the ACS, in 2004 alone, 230,110 men are expected to be
 diagnosed with the cancer and approximately 29,900 will die from the disease.
 
     About "Screen, Stage and Support"
     "Screen, Stage and Support" was started in 2001 by Cytogen Corporation to
 help patients, families and caregivers recognize the important role that
 proper screening, diagnosis, treatment and support can have for anyone
 affected by prostate cancer.  The campaign is designed to focus on the three
 key aspects of prostate cancer detection and treatment: screen, stage and
 support.
     Screen: When prostate cancer is diagnosed early, before it has spread
 outside the prostate gland, the odds for five-year survival are nearly
 100 percent through localized treatments.  The ACS recommends that men 50 and
 older get screened annually through a prostate-specific antigen (PSA) blood
 test and digital rectal exam (DRE); men at higher risk, such as
 African-Americans and those with a family history of prostate cancer, should
 begin early detection screening at age 45.  Stage:  Once a diagnosis of
 prostate cancer has been confirmed with a biopsy, doctors typically identify
 the "grade" and "stage" of the disease.  The grade is an estimate of the
 tumor's aggressiveness.  The stage refers to the extent and location of the
 cancer and whether or not it has spread beyond the prostate gland.  The grade
 and stage are the keys to defining the course of treatment the doctor will
 recommend.  Support:  Prostate cancer patients also require support in coping
 with the physical and emotional aspects of the disease, including the pros and
 cons of different treatment and palliative options, which can be obtained
 through patient advocacy groups such as the ACS, NPCC, and Prostate Cancer
 Foundation.
     The "Screen, Stage and Support" program has gained significant momentum
 and recognition over the past four years and it has continued to grow,
 providing patient education in the form of video, print and live seminars.
 For a free copy of the "Screen, Stage and Support" brochure, call
 1-800-833-3533 or visit http://www.cytogen.com, which is not part of this
 press release.
     In addition to the Manhattan screening event in front of the NASDAQ
 MarketSite, this year's program offers two additional days of free prostate
 cancer screening in New York City.  On September 8, the NPCC's "Drive Against
 Prostate Cancer" mobile screening unit will be at the Harlem YMCA from 9 a.m.
 to 12 p.m. and 2 p.m. to 6 p.m.  Then on September 10, the unit will be at the
 Bedford-Stuyvesant Restoration Corporation in Brooklyn from 9 a.m. to 12 p.m.
 and 2 p.m. to 6 p.m.
 
     About Cytogen Corporation
     Founded in 1980, Cytogen Corporation of Princeton, NJ, is a product-
 driven, oncology-focused biopharmaceutical company that develops and
 commercializes a balanced portfolio of oncology products that address the
 unmet medical needs of patients and the physicians that serve them.  Cytogen
 directly markets QUADRAMET(TM) (samarium Sm-153 lexidronam injection),
 PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111
 capromab pendetide, and NMP22(R) BLADDERCHEK(R) (nuclear matrix protein-22) in
 the United States.  Cytogen has exclusive United States marketing rights to
 COMBIDEX(R) (ferumoxtran-10), an investigational molecular imaging agent
 consisting of iron oxide nanoparticles for use in conjunction with magnetic
 resonance imaging to aid in the differentiation of cancerous and non-cancerous
 lymph nodes, which is under review by the U.S. Food and Drug Administration.
 Cytogen is also developing therapeutics targeting prostate-specific membrane
 antigen (PSMA), a protein highly expressed on the surface of prostate cancer
 cells and the neovasculature of solid tumors.  Full prescribing information
 for the Company's products is available at http://www.cytogen.com or by
 calling 1-800-833-3533.  For more information, please visit the Company's
 website at http://www.cytogen.com, which is not part of this press release.
 
     About Market Open Web Cam
     The Market Open ceremony can be viewed online through the NASDAQ web cam
 at http://www.nasdaq.com/reference/marketsite_about.stm.  Windows Media Player
 is required for the web cam to load properly.  Viewers are advised to access
 the web cam at 9:15 a.m. to allow time for loading; at 9:20 a.m. the web cam's
 view will be switched from the MarketSite Tower to inside the NASDAQ studio.
 
     This press release contains certain "forward-looking" statements within
 the meaning of the Private Securities Litigation Reform Act of 1995 and
 Section 21E of the Securities Exchange Act of 1934, as amended.  All
 statements, other than statements of historical facts, included in this press
 release regarding our strategy, future operations, financial position, future
 revenues, projected costs, prospects, plans and objectives of management are
 forward-looking statements.  Such forward-looking statements involve a number
 of risks and uncertainties and investors are cautioned not to put any undue
 reliance on any forward-looking statement.  There are a number of important
 factors that could cause Cytogen's results to differ materially from those
 indicated by such forward-looking statements.  In particular, Cytogen's
 business is subject to a number of significant risks, which include, but are
 not limited to: the risk of obtaining the necessary regulatory approvals; the
 risk of whether products result from development activities; the risk of
 shifts in the regulatory environment affecting sales of Cytogen's products
 such as third-party payor reimbursement issues; the risk associated with
 Cytogen's dependence on its partners for development of certain projects, as
 well as other factors expressed from time to time in Cytogen's periodic
 filings with the Securities and Exchange Commission (the "SEC").  As a result,
 this press release should be read in conjunction with Cytogen's periodic
 filings with the SEC.  The forward-looking statements contained herein are
 made only as of the date of this press release, and Cytogen undertakes no
 obligation to publicly update such forward-looking statements to reflect
 subsequent events or circumstances.
 
 SOURCE  Cytogen Corporation

RELATED LINKS

http://www.cytogen.com